Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
May 15, 2023 16:05 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris Reports First Quarter 2023 Financial Results
May 09, 2023 17:00 ET
|
Aeterna Zentaris Inc
– Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate recruitment for DETECT trial Actively seeking alternate development and...
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
April 05, 2023 07:55 ET
|
Aeterna Zentaris Inc
U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
March 23, 2023 08:05 ET
|
Aeterna Zentaris Inc
– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing strategy to streamline advancement of development programs, build upon growing...
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
March 16, 2023 08:05 ET
|
Aeterna Zentaris Inc
Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna...
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
January 17, 2023 08:05 ET
|
Aeterna Zentaris Inc
Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across...
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
January 10, 2023 08:05 ET
|
Aeterna Zentaris Inc
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
August 03, 2022 17:30 ET
|
Aeterna Zentaris Inc
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE...
Aeterna Zentaris Announces Effective Date of Share Consolidation
July 18, 2022 17:06 ET
|
Aeterna Zentaris Inc
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
July 15, 2022 16:15 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...